Home / Health / Microbiome Therapy Promises 77% Reduction in Newborn Food Allergies
Microbiome Therapy Promises 77% Reduction in Newborn Food Allergies
18 Nov
Summary
- Oral microbiome therapy shows promise in preventing food allergies in newborns
- Gut health central to overall health, may be linked to rise in food allergies
- Peanut allergies far more common today than in the past, experts seek causes
As of November 2025, health officials and advocates are intensely focused on understanding the root causes behind the growing food allergy crisis in the United States. With over 32 million Americans battling these conditions, the Food Allergy Fund (FAF) recently hosted a forum in Washington, D.C. to explore potential solutions.
At the event, FDA Chief Martin Makary emphasized the central role of gut health, noting that disruptions to the delicate balance of gut microbiomes may be a key driver behind the rise in food allergies. Researchers at Siolta Therapeutics are testing an oral microbiome therapy, STMC-103H, which has shown promising results in a Phase 2 trial involving 238 newborns with a family history of allergies. Early data suggests the therapy could reduce the risk of developing food allergies by 77%, indicating that improving gut bacteria early in life could prevent allergies before they start.
HHS Secretary Robert F. Kennedy, who has personal experience with his son's severe food allergies, observed that peanut allergies appear to be far more common among children today compared to when he was growing up. "When I was a kid, I never met anyone with a peanut allergy," he shared. "But by the time my son was 2, we'd been to the emergency room about 22 times." Kennedy emphasized the urgent need to uncover the underlying causes of this alarming trend.
